Business Context and Reporting Period
Company: IMMUCELL CORP (Delaware)
Filing Type: Form 10-Q (Unaudited Quarterly Report)
Period Ended: March 31, 1998
Business Overview: The Company develops and markets products based on passive antibody technology, including First Defense and the Kamar Heatmount Detector. It also invests in joint ventures for lactoferrin production and water diagnostics.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Total Revenues | $1,335,034 | $1,300,240 |
| Net Profit | $219,261 | $152,485 |
| Net Profit Per Share (Diluted) | $0.08 | $0.06 |
| Net Cash from Operating Activities | $461,098 | $102,473 |
| Cash and Cash Equivalents (Ending) | $1,404,781 | $1,061,287 |
| Total Debt (Current + Long Term) | $832,592 | $831,542 |
| Working Capital | $1,845,203 | $1,642,363 |
Gross Margin: Improved to 58% of product sales in Q1 1998 from 56% in Q1 1997.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 3% year-over-year. Product sales rose 8% ($102,000) driven by a 9% increase in sales of core products (First Defense and Kamar Heatmount Detector).
- Income Composition: Technology licensing income dropped to $0 from $75,000 in the prior year. Grant income increased slightly to $24,636 from $16,881.
- Profitability: Net profit increased 44% to $219,261, aided by improved manufacturing efficiencies and a reduction in General and Administrative expenses ($23,000 decrease).
- Cash Flow: Net cash provided by operating activities surged to $461,098 from $102,473, primarily due to a $155,872 decrease in accounts receivable.
Outlook, Risks, and Management Commentary
- Seasonality: Management notes that product sales are seasonally highest in the first quarter, which contributed to the reported profitability. Operating losses are expected in future quarters as the Company invests in R&D.
- R&D Strategy: The Company continues to invest in Phase I/II clinical trials for new products (e.g., TravelGAM for Travelers' Diarrhea) with the strategy of seeking corporate partners to fund further development in exchange for marketing rights.
- Joint Ventures: Equity earnings of $13,000 were recognized from Clearwater Diagnostics Company (CDC). AgriCell Company recently began commercial production of bovine lactoferrin.
- Subsequent Event (Debt Refinancing): In May 1998, the Company refinanced all outstanding bank debt with a new $480,000 mortgage loan secured by its building. The new loan carries a fixed interest rate of 8.62% for the first five years.
- Liquidity: The Company holds a $710,000 NIH grant (approx. $485,000 remaining) and believes it has sufficient capital to meet requirements for the next 12 months.
Investor Verification Checklist
- Seasonal Profitability: Verify if profitability is consistent in non-first quarters given the stated seasonality.
- Debt Refinancing Terms: Confirm the impact of the May 1998 refinancing on future interest expenses and principal repayment schedules.
- Grant Dependency: Assess the reliance on the NIH grant ($485k remaining) to fund R&D for TravelGAM and other projects.
- Joint Venture Performance: Monitor the commercial ramp-up of AgriCell and the regulatory status of CDC's Crypto-Scan test with the EPA.
- Revenue Concentration: Note that 95% of product sales come from two specific products (First Defense and Kamar Heatmount Detector).